Engage smarter. Location Messaging Hyper-relevant, location-based messaging with geo-triggers and beacons. That's where the Wall Street pros can lend a hand. More news. United States. Investment themes. Simply Wall St has no position in the stocks mentioned. Top News. VIATRIS Best Pokies In Melbourne. The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14, patients with top-line data expected in the second half of See ICPT stock analysis on TipRanks Gilead Sciences GILD Gilead has had a year like a firework — fast up and fast down. The directors present their report on the consolidated entity (referred to hereafter as the “Group”) consisting of OtherLevels Holdings Limited (“OtherLevels” or the “ompany”) and the entities it controlled, for the year ended 30 June HotCopper has news, discussion, prices and market data on OTHERLEVELS HOLDINGS LIMITED. Join the HotCopper ASX share market forum today for free. OtherLevels Holdings LimitedACN Chairman and Managing Director’s letter 3 The Company also sees further opportunities driven by loyalty, membership and visitor website conversion within the travel and hospitality sectors. OtherLevels already has one of the world’s top 3 hotel operators. OtherLevels Holdings Limited (ASX: OLV) (“OtherLevels”), is pleased to announce a large international bookmaker and gaming. OtherLevels Holdings Limited ACN Chairman and Managing Director’s message 3 continuously strive to exceed customer expectations. Their contribution is a major reason why the Company is able to retain and grow existing clients.

Fundamental Rankings. Stock Screener Home. MarketScreener tools. Dynamic chart. Our Services. MarketScreener Portfolios.

Add to my list. Upcoming sector events. More events. All rights reserved. Log in E-mail. Engage smarter. Retain longer. Reduce acquisition costs, drive retention and increase revenue, with relevant, intelligent messaging.

Find out more. But on the other hand, the company made a loss during the last year, which makes us a little cautious.

Given that insiders also own a fair bit of OtherLevels Holdings we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.

For example, OtherLevels Holdings has 4 warning signs and 2 which can't be ignored we think you should know about.

Of course OtherLevels Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body.

We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team simplywallst. This article by Simply Wall St is general in nature.

It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.

Simply Wall St has no position in the stocks mentioned. We aim to bring you long-term focused research analysis driven by fundamental data.

Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

A new year, a new addition to the stock portfolio — what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom.

But the markets are up. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That's where the Wall Street pros can lend a hand.

Not to mention each has earned a Moderate or Strong Buy consensus rating. Esperion ESPR We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels — a major factor contributing to heart disease.

In February , both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.

The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14, patients with top-line data expected in the second half of The study covers 1, locations in 32 countries around the world.

Listed company. Sector News. All Analysis. Stock Picks. All stock picks. My Portfolio. My Watchlists. Investment themes.

Top News. Top Fundamentals. Top Technicals. Top Movers. Top Fundamentals. Top Technicals. Top Movers. Investment selections.

Technical Rankings. Fundamental Rankings. Stock Screener Home. MarketScreener tools. Dynamic chart. Our Services. MarketScreener Portfolios.